Viatris Inc (VTRSI)

10.735 0.000 (0.00%)
Close EUR Disclaimer

Viatris Inc Company Profile

Equity Type
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Contact Information
Canonsburg,15317 United States
724 514 1800
Top Executives
Mark W. Parrish 67 2009 Independent Vice Chairman & Lead Independent Director
Melina E. Higgins 55 2013 Independent Non-Executive Chairman
Scott Andrew Smith 61 2022 CEO & Director
Harry A. Korman 67 2001 Independent Non-Executive Director
Wyllie Don Cornwell 76 2020 Independent Director
James Marshall Kilts 76 2020 Independent Director
Elisha Wade Finney 63 2022 Independent Director
Leo Groothuis 52 2023 Independent Director
Robert J. Coury 63 2002 Chairman Emeritus & Senior Strategic Advisor
Rajiv Malik 63 2007 Director
JoEllen Lyons Dillon 60 2014 Independent Non-Executive Director
Richard A. Mark 70 2020 Independent Non-Executive Director
Rogerio Vivaldi Coelho 60 2024 Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles